Download PDF
Thromb Haemost 2011; 105(06): 1118-1120
DOI: 10.1160/TH10-12-0802
Letters to the Editor
Schattauer GmbH

Can recombinant thrombomodulin play a preventive role for veno-occlusive disease after haematopoietic stem cell transplantation?

Shosaku Nomura
1   First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
,
Ryotaro Ozasa
1   First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
,
Takahisa Nakanishi
1   First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
,
Shinya Fujita
1   First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
,
Michihiko Miyaji
1   First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
,
Shinichiro Mori
1   First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
,
Takashi Yokoi
1   First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
,
Tomoki Ito
1   First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
,
Kazuyoshi Ishii
2   Division of Hematology, Kishiwada City Hospital, Osaka, Japan
› Author Affiliations
Further Information

Publication History

Received: 17 December 2010

Accepted after major revision: 05 March 2011

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Juttner CA, To LB, Ho J. et al. Early lympho-hematopoietic recovery after autografting using peripheral blood stem cell in acute nonlymphoblastic leukemia. Transplant Proc 1998; 20: 40-42.
    PubMedSearch in Google Scholar
  • 2 Stoffel N, Rysler C, Buser A. et al. Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy. Thromb Haemost 2010; 103: 1228-1232.
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Rowbottom AW, Riches PG, Downie C. et al. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogenic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 635-641.
    PubMedSearch in Google Scholar
  • 4 Testa S, Manna A, Porcellini A. et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 1996; 18: 383-388.
    PubMedSearch in Google Scholar
  • 5 Nishida T, Hamaguchi M, Hirabayashi N. et al. Intestinal thrombotic microangiopathy after allogenic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1143-1150.
    CrossrefPubMedSearch in Google Scholar
  • 6 Hassan M, Ljungman P, Ringden O. et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-924.
    CrossrefPubMedSearch in Google Scholar
  • 7 de Jonge ME, Huitema AD, Beijnen JH. et al. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006; 94: 1226-1230.
    CrossrefPubMedSearch in Google Scholar
  • 8 Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008; 41: 229-237.
    CrossrefPubMedSearch in Google Scholar
  • 9 Cutler C, Kim HT, Ayanian S. et al. Prediction of veno-acclusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant 2010; 16: 1180-1185.
    CrossrefPubMedSearch in Google Scholar
  • 10 Attal M, Huguer F, Rubie H. et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834-2840.
    PubMedSearch in Google Scholar
  • 11 Nomura S, Ishii K, Inami N. et al. Evaluation of angiopoietins and cell-derived microparticle after stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 766-774.
    CrossrefPubMedSearch in Google Scholar
  • 12 Saito H, Maruyama I, Shimazaki S. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41.
    CrossrefPubMedSearch in Google Scholar
  • 13 Van lersel T, Stroissnig H, Giesen P. et al. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost 2011; 105: 302-312.
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Kumar S, DeLeve LD, Kamath P. et al. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589-598.
    CrossrefPubMedSearch in Google Scholar
  • 15 Richardson PG, Elias AD, Krishnan A. et al. Treatment of veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744.
    PubMedSearch in Google Scholar
  • 16 Richardson PG, Murakami C, Jin Z. et al. Multi-institutional of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343.
    CrossrefPubMedSearch in Google Scholar
  • 17 Zhou O, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994; 71: 507-510.
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Ho VT, Linden E, Revta C. et al. Hepatic veno-acclusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost 2007; 33: 373-388.
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Ikezoe T, Togitani K, Komatsu N. et al. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 783-785.
    CrossrefPubMedSearch in Google Scholar
  • 20 Sakai M, Ikezoe T, Bandobashi K. et al. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 803-805.
    CrossrefPubMedSearch in Google Scholar
  • 21 Abeyama K, Stern DM, Ito Y. et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005; 115: 1267-1274.
    CrossrefPubMedSearch in Google Scholar
  • 22 Hatada T, Wada H, Nobori T. et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005; 94: 975-979.
    Thieme ConnectPubMedSearch in Google Scholar